ESMO Preceptorship on Lung Cancer and Other Thoracic Malignancies 2022: Paris
- Start date
- 17 Nov 2022
- End date
- 18 Nov 2022
- Location
- Paris, France
Learning objectives
- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma
Accreditation
The programme of this event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Fabrice Barlesi, France
- Solange Peters, Switzerland
- David Planchard, France
Supported by
